ANURAS2025-10-012025-12-31ANURAS2025-04-012025-12-31ANURAS2025-10-012025-12-31in-capmkt:OtherExpenses1MemberANURAS2025-04-012025-12-31in-capmkt:OtherExpenses1MemberANURAS2025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1ANURAS2025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2ANURAS2025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1ANURAS2025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss2ANURAS2025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1ANURAS2025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss2ANURAS2025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1ANURAS2025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares543275ANURASNOTLISTEDINE930P01018ANUPAM RASAYAN INDIA LIMITEDMain BoardEquity2025-04-012026-03-312026-02-142026-02-07INRMillionsQuarterlyThird quarterSingle segmentManufacturing of Industrial Chemicals2026-02-1409:06:002026-02-1409:35:00Not applicable2025-10-012025-12-31UnauditedConsolidated5124470000210100005145480000269696000003888000018050000035159000034472000093333000045459800005995000000599500000122120000-128550000-643000006059300000000605930000-388700005670600004904100001155200004510100001160700001138480000104.314.31004.314.311. The above Consolidated Financial results for the Quarter and Nine months ended December 31 2025 have been prepared by the Company in accordance with Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations 2015 as amended and were reviewed by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on February 14 2026. <BR> <BR> 2. Based on the management approach as defined in Ind AS 108 Operating Segments the Chief Operating Decision Maker evaluates the companys performance and allocates resources based on an analysis of various performance indicators of business segments in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence disclosure of segment wise information is not required and accordingly not provided. <BR> <BR> 3. The Board of Directors of the Company at its meeting held on July 15 2025 has approved the allotment of 3914886 fully paid up equity shares at an issue price of INR 945.11 per share comprising face value of INR 10 per share and premium of INR 935.11 per share on preferential allotment basis upon conversion of equal number of warrants after receipt of 75 percent amount i.e. INR 2775 million. The entire amount of INR 2775 million so received have been utilised for the repayment of Loans and General Corporate purposes by December 31 2025. <BR> <BR> 4. The Company has investment in the following Subsidiary companies and into an Associate Company of Wholly owned subsidiary through a WOS as on December 31 2025 and accordingly Consolidated Financial Results for the Quarter and Nine months ended on December 31 2025 include following entities <BR> <BR> Name of the Company and Nature of Relationship <BR> a Jainam Intermediates Private Limited <BR> Wholly owned subsidiary. <BR> b Tanfac Industries Limited <BR> Subsidiary Company over which the Company exercises effective control. <BR> c ARIL Transmodal Logistics Private Limited <BR> Wholly owned subsidiary. <BR> d ARIL Fluorospeciality Private Limited <BR> Wholly owned subsidiary. <BR> e Anupam Japan GK <BR> Wholly owned subsidiary. <BR> f Anupam Europe AG <BR> Wholly owned subsidiary. <BR> g Anupam USA LLC <BR> Wholly owned subsidiary. <BR> h Anupam General Trading FZE <BR> Wholly owned subsidiary. <BR> i Tangent Science Private Limited <BR> An Associate Company of Wholly owned subsidiary of the Company. <BR> <BR> 5. The figures of the previous period have been regrouped rearranged and or recasted wherever considered necessary.2025-04-012025-12-31UnauditedConsolidated1729672000014805000017444770000105624800000-6448800005575500001067990000972230000294603000015461400000198337000001983370000393080000-717400003213400000166203000000001662030000-4388000016181500001274710000387320000123004000038812000011384800001011.3411.340011.3411.34Other Expenses933330000Other Expenses2946030000Gain/(loss) on remeasurements of the defined benefits plan-12060000Income tax (expense)/income on remeasurements of the defined benefits plan4310000-7750000Gain/(loss) on remeasurements of the defined benefits plan-16610000Income tax (expense)/income on remeasurements of the defined benefits plan5940000-1067000000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge-31120000Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge0-31120000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge-33210000Income tax (expense)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge0-3321000000-38870000-43880000